1. Hu, Yongxian, Zhang, Mingming, Yang, Tingting, Wang, Dongrui, Huang, He. . Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis. In The New England journal of medicine, 390, 1467-1480. doi:10.1056/NEJMoa2313812. https://pubmed.ncbi.nlm.nih.gov/38657244/
2. Lu, Peihua, Liu, Ying, Yang, Junfang, Li, Jianqiang, Huang, Xiaojun. . Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. In Blood, 140, 321-334. doi:10.1182/blood.2021014498. https://pubmed.ncbi.nlm.nih.gov/35500125/
3. Oh, Bernice L Z, Shimasaki, Noriko, Coustan-Smith, Elaine, Yeoh, Allen E J, Campana, Dario. 2024. Fratricide-resistant CD7-CAR T cells in T-ALL. In Nature medicine, 30, 3687-3696. doi:10.1038/s41591-024-03228-8. https://pubmed.ncbi.nlm.nih.gov/39227445/
4. Gomes-Silva, Diogo, Srinivasan, Madhuwanti, Sharma, Sandhya, Brenner, Malcolm K, Mamonkin, Maksim. 2017. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. In Blood, 130, 285-296. doi:10.1182/blood-2017-01-761320. https://pubmed.ncbi.nlm.nih.gov/28539325/
5. Watanabe, Norihiro, Mo, Feiyan, Zheng, Rong, Brenner, Malcolm K, Mamonkin, Maksim. 2022. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. In Molecular therapy : the journal of the American Society of Gene Therapy, 31, 24-34. doi:10.1016/j.ymthe.2022.09.003. https://pubmed.ncbi.nlm.nih.gov/36086817/
6. Chiesa, Robert, Georgiadis, Christos, Syed, Farhatullah, Vora, Ajay, Qasim, Waseem. 2023. Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. In The New England journal of medicine, 389, 899-910. doi:10.1056/NEJMoa2300709. https://pubmed.ncbi.nlm.nih.gov/37314354/
7. Bonilla, F A, Kokron, C M, Swinton, P, Geha, R S. . Targeted gene disruption of murine CD7. In International immunology, 9, 1875-83. doi:. https://pubmed.ncbi.nlm.nih.gov/9466315/
智鼠故事 
